Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
Revenue (TTM)
$3 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
44.78
EV/EBITDA
0.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-13
Face value
--
Shares outstanding
1,088,192
CFO
$-31.91 Mln
EBITDA
$-39.77 Mln
Net Profit
$-51.04 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NanoVibronix (NAOV)
| -- | -43.4 | -63.3 | -99.6 | -93.2 | -81.8 | -63.1 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
NanoVibronix (NAOV)
| -48.4 | -77.2 | -51.5 | 36.1 | -73.2 | -21.3 | -22.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
NanoVibronix (NAOV)
|
2.3 | 4.4 | 2.7 | -3.6 | -259.4 | -9.1 | -- | 0.0 |
| 6.9 | 20.2 | 0.7 | -84.3 | -11,540.4 | -- | -- | 1.4 |
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product... portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Tyler, Texas. Read more
CEO & Director
Mr. Brian M. Murphy
CEO & Director
Mr. Brian M. Murphy
Headquarters
Tyler, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of NanoVibronix Inc (NAOV) is $2.32 (NASDAQ) as of 13-Jan-2026 09:30 EDT. NanoVibronix Inc (NAOV) has given a return of -93.2% in the last 3 years.
Since, TTM earnings of NanoVibronix Inc (NAOV) is negative, P/E ratio is not available.
The P/B ratio of NanoVibronix Inc (NAOV) is 0.04 times as on 13-Jan-2026, a 99 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.05
|
0.30
|
|
2023
|
-0.06
|
0.05
|
|
2022
|
-0.08
|
0.13
|
|
2021
|
-2.04
|
4.61
|
|
2020
|
-3.75
|
6.78
|
The 52-week high and low of NanoVibronix Inc (NAOV) are Rs 1,625.00 and Rs 2.10 as of 05-Apr-2026.
NanoVibronix Inc (NAOV) has a market capitalisation of $ 4 Mln as on 13-Jan-2026. As per SEBI classification, it is a Small Cap company.
Before investing in NanoVibronix Inc (NAOV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.78
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.